On 27 June 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ebymect. The marketing authorisation holder for this medicinal product is AstraZeneca AB.
“Ebymect is indicated in adults aged 18 years and older with for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
- in patients inadequately insufficiently controlled on their maximally tolerated dose of metformin alone
- in combination with other glucose-lowering medicinal products, including insulin, for the treatment of diabetes in patients inadequately insufficiently controlled with metformin and these medicinal products (see sections 4.4, 4.5 and 5.1 for available data on different combinations)
- in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.
For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.”
Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
1New text shown in bold; removed text as strikethrough.
|Agency product number||
|International non-proprietary name (INN) or common name||
Diabetes Mellitus, Type 2
|Date opinion adopted||
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 201525/09/2015